COULD ORAL ETs

HELP GIVE BACK

SOME OF WHAT TIME TOXICITY TAKES?

While there will be a degree of time toxicity in any cancer treatment, oral formulations may represent an opportunity to relieve some of the time toxicity caused when treating ER+, HER2– MBC1-4

A 2023 survey by Ipsos in collaboration with Living Beyond Breast Cancer found the majority of patients with ER+, HER2– MBC* would be comfortable receiving an IM injection when recommended by their oncologist.5

*Research conducted by Ipsos in collaboration with Living Beyond Breast Cancer and funded by Eli Lilly and Company. Survey participants have not reported that they previously received IM injectable SERD treatment.5

3 out of 4 patients would prefer a daily oral treatment instead of traveling to their oncologist’s office to receive an IM injection.5 62% cite the lack of injection site soreness as another key benefit of oral therapies.5

Oral treatment options may have additional perceived benefits to multiple aspects of patient wellness, including5:

Car icon

Fewer appointments, less travel

More than half of patients with MBC (61%) noted that an oral medication they take at home would lessen the financial burden associated with traveling to their oncologist’s office5

Checkbox icon

Maintaining their routine

73% of patients believe taking an oral medication would not affect their daily routine5

Hand holding a plus sign

A sense of control over their disease

3 out of 4 patients state that taking a daily oral formulation makes them feel they are actively tackling their disease every day5

Beyond convenience, oral therapies could help patients feel more in control of their daily routine.1,6

The benefits of oral ETs may go beyond a formulation change.1,7

For the past 20 years, there has been a concerted focus on improving the therapeutic effects of ET.6-9

Emerging research has shown that novel oral endocrine therapies have the potential to improve ER degradation by providing6,7:

Image of a pill with 3 descriptions stating: 1. consistent oral bioavailability 2. prolonged therapeutic levels and 3. steady suppression of estrogen receptors.

Now is the time to reevaluate the treatment experience for patients with ER+, HER2– MBC and the burden of time toxicity.

IM injections have been an effective standard of care in ER+, HER2– MBC.7

However, oral formulations have the potential to reduce the current time toxicity burden (the time spent in pursuing care) and optimize ER degradation.2,7

Could oral ETs change patient experiences and perceptions?

ER=estrogen receptor; ER+=estrogen receptor–positive; ET=endocrine therapy; HER2–=human epidermal growth factor receptor 2–negative; IM=intramuscular; MBC=metastatic breast cancer; SERD=selective estrogen receptor degrader.

References:

  1. Hanna K, Mayden K. The use of real-world evidence for oral chemotherapies in breast cancer. J Adv Pract Oncol. 2021;12(suppl 2):13-20. doi:10.6004/jadpro.2021.12.2.12
  2. Rocque GB, Williams CP, Ingram SA, et al. Health care-related time costs in patients with metastatic breast cancer. Cancer Med. 2020;9(22):8423-8431. doi:10.1002/cam4.3461
  3. Johnson WV, Blaes AH, Booth CM, et al. The unequal burden of time toxicity. Trends Cancer. 2023;9(5):373-375. doi:10.1016/j.trecan.2023.01.006
  4. Eek D, Krohe M, Mazar I, et al. Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature. Patient Prefer Adherence. 2016;10:1609-1621. doi:10.2147/PPA.S106629
  5. Ipsos. Understanding patients with metastatic breast cancer — a preference for oral treatments. Accessed February 22, 2024. https://www.ipsos.com/sites/default/files/ct/news/documents/2024-02/Metastatic%20Breast%20Cancer-%20Topline.pdf
  6. Wang Y, Tang SC. The race to develop oral SERDs and other novel estrogen receptor inhibitors: recent clinical trial results and impact on treatment options. Cancer Metastasis Rev. 2022;41(4):975-990. doi:10.1007/s10555-022-10066-y
  7. Hernando C, Ortega-Morillo B, Tapia M, et al. Oral selective estrogen receptor degraders (SERDs) as a novel breast cancer therapy: present and future from a clinical perspective. Int J Mol Sci. 2021;22(15):7812. doi:10.3390/ijms22157812
  8. Lin X, Xiang H, Luo G. Targeting estrogen receptor α for degradation with PROTACs: A promising approach to overcome endocrine resistance. Eur J Med Chem. 2020;206:112689. doi:10.1016/j.ejmech.2020.112689
  9. Wittmann BM, Sherk A, McDonnell DP. Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators. Cancer Res. 2007;67(19):9549-60. doi:10.1158/0008-5472.CAN-07-1590